Ocular Therapeutix：AXPAXLI 有望將視網膜治療能量轉化為商業護城河 (NASDAQ:OCUL)
· seekingalpha.com
Ocular Therapeutix 瞄準於 2027 年推出 AXPAXLI，用於治療濕性老年性黃斑部病變 (wet AMD) 及視網膜疾病，憑藉強勁的第三期臨床數據，預計於 2026 年第四季向 FDA 提交新藥申請 (NDA)。點擊此處閱讀更多資訊。
My bullish view on Ocular Therapeutix ( OCUL ) is not just based on AXPAXLI becoming another long-duration treatment for wet AMD. I think AXPAXLI could also bec...